Genenta Science S.p.A (GNTA) Non-Current Assets (2020 - 2025)
Genenta Science S.p.A (GNTA) posted Non-Current Assets of $2.2 million for Q4 2025, up 251.45% sequentially from $632527.8 in Q2 2025, and up 492.66% YoY from $375094.1 in Q4 2024.
Genenta Science S.p.A (GNTA) Non-Current Assets (2020 - 2025) Analysis & Trends
Genenta Science S.p.A has reported Non-Current Assets for 6 years, with the latest figure at $2.2 million in Q4 2025.
- Quarterly Non-Current Assets rose 492.66% year-over-year to $2.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.2 million (up 492.66% YoY) and the FY2025 annual result came in at $2.2 million, up 492.66% from the prior year.
- Non-Current Assets improved to $2.2 million in Q4 2025 per GNTA's latest filing, from $632527.8 in the prior quarter.
- Over five years, Non-Current Assets peaked at $2.4 million in Q2 2023 and troughed at $375094.1 in Q4 2024.
- A 5-year average of $1.3 million and a median of $1.2 million in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets slumped 79.96% in 2024, then surged 492.66% in 2025.
- Over 5 years, Non-Current Assets stood at $1.5 million in 2021, then gained by 20.76% to $1.8 million in 2022, then slumped by 32.98% to $1.2 million in 2023, then plunged by 68.04% to $375094.1 in 2024, then soared by 492.66% to $2.2 million in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $2.2 million, $632527.8, and $375094.1 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Genenta Science S.p.A | 25.03 Mn | -34.07 Mn | - | 2.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.22 Mn |
| Jun 30, 2025 | 632,527.75 |
| Dec 31, 2024 | 375,094.08 |
| Jun 30, 2024 | 482,159.18 |
| Dec 31, 2023 | 1.17 Mn |
| Jun 30, 2023 | 2.41 Mn |
| Dec 31, 2022 | 1.75 Mn |
| Jun 30, 2022 | 927,568.90 |
| Dec 31, 2021 | 1.45 Mn |
| Dec 31, 2020 | 1.15 Mn |